Available online on 15.6.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access **Review Article**

Virtual Humans in Drug Development: Integrating Digital Models with Pharmacological Science

Mohamed Afsal A[1*], Dhivya G[1], Gowrishallini P[3], Syed Ali Fathima[2], Devi Sowndarya N[5], Suprraja S[4]

[1]Assistant Professor, Department of Pharmacology, Sri Ramakrishna Institute of Paramedical Sciences, College of Pharmacy, Coimbatore, Tamil Nadu, India

[2]Sri Ramakrishna Institute of Paramedical Sciences, College of Pharmacy, Coimbatore, Tamil Nadu, India

[3] PSG Institute of Medical Sciences, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India

[4]Department of Pharmacology, Karpagam Academy of Higher Education, Faculty of Pharmacy, Coimbatore, Tamil Nadu, India

[5]Department of Pharmaceutics, Hillside College of Pharmacy, Bangalore, Karnataka, India

A B S T R A C T

The conventional pathway of drug development is laborious, costly, and laden with high attrition rates. Recent advances in computational biology have spotlighted the potential of virtual human models, also known as in-silico human avatars, to revolutionize pharmacological research. This review aims to explore the potential of these digital tools in transforming drug discovery and development.These computer-generated, physiology-based simulations replicate biological systems and offer a safe, cost-effective, and ethical alternative for drug testing and disease modeling. In-silico pharmacology allows researchers to perform complex simulations of pharmacokinetics (PK), pharmacodynamics (PD), toxicity, and drug-disease interactions using virtual models that emulate human anatomy and physiology. This approach is increasingly valuable given the ethical constraints of animal testing and the need for accelerated drug discovery timelines. The development of digital twins, which represent the virtual counterpart of real patients, further empowers precision medicine and individualized therapy selection. By integrating artificial intelligence (AI), machine learning (ML), and physiologically based pharmacokinetic (PBPK) models with these avatars, predictive accuracy and the personalization of therapeutic strategies are significantly enhanced.This review discusses the core components, applications, challenges, and regulatory landscapes surrounding virtual human models in drug development.

Keywords: In-Silico Pharmacology; Virtual Humans; Drug Development; Digital Twins; Machine Learning; Advanced AI Clinical Trial.

A R T I C L E I N F O: Received 12 Jan. 2025; Review Complete 14 March. 2025; Accepted 14 April 2025. ; Available online15 June. 2025

Cite this article as:
Mohamed Afsal A, Dhivya G, Gowrishallini P, Syed Ali Fathima, Devi Sowndarya N, Suprraja S, Virtual Humans in Drug Development: Integrating Digital Models with Pharmacological Science, Asian Journal of Pharmaceutical Research and Development. 2025; 13(3):145-152, DOI: http://dx.doi.org/10.22270/ajprd.v13i3.1573

*Address for Correspondence:
Mohamed Afsal A, Assistant Professor, Department of Pharmacology, Sri Ramakrishna Institute of Paramedical Sciences, College of Pharmacy, Coimbatore, Tamil Nadu, India

INTRODUCTION

Drug development is a complex, multistep, and resource-intensive endeavor that typically spans over a decade and demands investment exceeding billions of dollars before a single therapeutic entity receives regulatory approval for market access. This long and arduous journey encompasses various phases, including drug discovery, preclinical testing, multiple stages of clinical trials, and regulatory review, each of which requires substantial financial resources, scientific expertise, and time. The stringent regulatory standards imposed by authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) further extend the timeline, emphasizing the need for highly reliable and predictive methods in early-stage research.

Historically, this process has relied on in-vitro assays and in-vivo animal models to predict efficacy and safety outcomes. In-vitro techniques, which involve studying biological processes outside their normal biological context and in-vivo studies using animal models have long formed the backbone of preclinical research. These methods have been instrumental in advancing our understanding of pharmacokinetics, pharmacodynamics, toxicology, and therapeutic mechanisms. Despite their central role, in-vitro and in-vivo models often have inherent limitations when translating results from experimental setups to the complex and variable physiology of human beings.

While these methods have served as cornerstones of pharmacological advancement, they often fall short when extrapolated to human biology due to significant interspecies differences, leading to high attrition rates in clinical trials. Animal models, though biologically similar in some respects, differ significantly from humans at genetic, molecular, metabolic, and immunological levels. Consequently, a drug candidate demonstrating promising results in animal studies may fail during human clinical trials, resulting in massive financial losses and wasted resources. Attrition rates, especially in the transition from Phase II to Phase III clinical trials, remain alarmingly high, underlining the pressing need for more predictive and human-relevant research models.

Moreover, animal testing raises ethical dilemmas and contributes to elevated costs and extended development timelines. The use of animals in research, while historically justified by the necessity to predict human outcomes, faces increasing scrutiny from ethical perspectives and animal rights organizations. Furthermore, the logistical complexities of animal housing, care, and regulatory compliance add significantly to the overall cost and duration of drug development programs, motivating researchers and pharmaceutical industries to seek viable alternatives that uphold both ethical standards and scientific rigor.

In response to these longstanding challenges, in-silico pharmacology has emerged as a transformative paradigm. This innovative field leverages advances in computational modeling, bioinformatics, systems biology, and artificial intelligence to simulate and predict biological responses to therapeutic interventions. In-silico approaches not only aim to streamline drug discovery and development but also provide unprecedented insights into disease mechanisms and patient variability, marking a fundamental shift in the traditional research paradigm.

In particular, the development and utilization of virtual human models in comprehensive, computer-generated representations of human physiological and pathological systems have provided researchers with innovative tools to simulate drug action, optimize treatment regimens, and assess disease progression in silico. These sophisticated models integrate vast datasets encompassing genomics, proteomics, metabolomics, and clinical information to faithfully replicate human biological processes at multiple organizational levels. Virtual human models can simulate individual patient profiles, account for genetic polymorphisms, predict therapeutic outcomes, and assess potential adverse effects even before clinical trials commence, thereby significantly reducing reliance on animal models and human subjects in early research phases.

These virtual platforms replicate the complexities of human anatomy and physiology across multiple biological scales, from molecular to systemic levels, thereby providing a powerful, ethical, and economically viable alternative to traditional approaches. By enabling multi-scale modeling from molecular interactions and cellular pathways to tissue responses and whole-organ functions, virtual human platforms bridge the translational gap between experimental research and clinical application. Their ability to simulate large, diverse patient populations also offers a unique advantage in identifying potential responders and non-responders, thus paving the way toward precision medicine. Ultimately, the strategic integration of virtual humans into the drug development pipeline holds the promise of expediting discovery, minimizing risks, enhancing success rates, and fostering more ethical and sustainable biomedical innovation [1-5, 24,31,37].

IN- SILICO MODELING AND SIMULATION TECHNIQUES

The methodological underpinnings of virtual human simulations draw from systems biology, computational physiology, pharmacokinetics, and bioinformatics. Systems biology offers a holistic perspective, emphasizing the interconnectivity between various biological components, while computational physiology focuses on the mathematical modeling of biological functions. Pharmacokinetics provides the foundation for understanding the dynamic behavior of drugs within the body, and bioinformatics enables the management, integration, and analysis of complex biological datasets. Together, these interdisciplinary approaches establish a robust framework for constructing highly detailed and predictive virtual human models, capable of simulating intricate physiological and pathological phenomena with remarkable accuracy.

Central to these frameworks are the initiatives like the Virtual Physiological Human (VPH) and the Human Physiome Project, which pioneered the creation of modular, reusable, and open-access models for simulating a wide array of physiological functions. The Virtual Physiological Human initiative, supported by the European Commission, aimed to create comprehensive, integrative models of human physiology to improve healthcare outcomes and biomedical research. Similarly, the Human Physiome Project sought to mathematically describe human biological systems, offering standardized frameworks for modeling organ systems and whole-body functions. These large-scale, collaborative projects set a precedent for data sharing, model standardization, and multidisciplinary collaboration in computational biomedicine, greatly facilitating progress in the field of virtual human development.

These models integrate diverse biological data, including genomic, proteomic, cellular, tissue-level, and organ-specific information, to construct dynamic representations of human function and disease [6,7,8,26,31]. By incorporating multilayered biological information, virtual models achieve a high degree of fidelity in replicating human physiological responses.

Genomic data informs variations in genetic profiles, proteomic data sheds light on protein interactions and signaling pathways, while cellular and tissue-level information captures structural and functional dynamics at microscopic scales. Organ-specific parameters enable the accurate simulation of systemic behaviors, such as cardiovascular dynamics or hepatic metabolism, allowing for holistic and mechanistic representations of both healthy and diseased states.

In-silico pharmacology platforms often incorporate physiologically based pharmacokinetic (PBPK) modeling to simulate the ADME (Absorption, Distribution, Metabolism, and Excretion) profiles of pharmaceutical agents. PBPK modeling stands as a cornerstone of predictive pharmacology, offering detailed insights into how a drug behaves once administered to the body. By mimicking the flow of compounds through various compartments representing organs and tissues, PBPK models facilitate a mechanistic understanding of drug disposition under a wide range of physiological and pathophysiological scenarios. They bridge the gap between preclinical findings and clinical outcomes, enhancing translational success.

Figure 1: Virtual Physiological Human Model

Figure 2: Virtual Neurological Human Model

PBPK models consist of mathematical representations of the human body, segmented into compartments corresponding to organs and tissues, each defined by specific parameters like blood flow rates, enzyme activity, tissue volumes, and membrane permeability. These compartments are interconnected through equations that govern the transport, metabolism, and elimination of the drug, ensuring a physiologically realistic simulation of its journey through the body. Parameters such as blood perfusion rates, enzymatic kinetics (e.g., CYP450 enzyme activity), tissue binding affinities, and membrane transport properties are integral to building an accurate and predictive PBPK model.

These parameters are either experimentally derived or estimated using computational techniques, allowing the simulation of drug kinetics under varying physiological and pathological conditions [13,14,27]. Experimental methods such as in-vitro assays and clinical studies contribute to parameter acquisition, while advanced computational approaches enable extrapolation and scaling when empirical data are scarce. By adjusting parameters to reflect disease states (e.g., hepatic impairment, renal dysfunction) or demographic variables (e.g., age, gender, ethnicity), PBPK models can predict drug behavior across a broad spectrum of clinical contexts, supporting safer and more effective therapeutic decision-making.

To implement these complex models, industry-standard software platforms such as Simcyp®, GastroPlus®, and PK-Sim® are used. These tools are specifically designed to facilitate the development, validation, and application of PBPK models in both regulatory and research settings. Simcyp® provides a simulation environment for evaluating pharmacokinetics and pharmacodynamics in virtual populations, GastroPlus® focuses on gastrointestinal absorption and systemic distribution, while PK-Sim® offers a comprehensive platform for PBPK modeling across various species, including humans. These tools facilitate high-resolution simulations tailored to diverse population subsets, including pediatric, geriatric, pregnant, and diseased individuals. By incorporating demographic-specific physiological parameters such as age-related changes in organ function, enzyme activity, and plasma protein levels these software platforms enable the modeling of vulnerable or underrepresented populations, thereby improving the generalizability and applicability of pharmacological findings.

The platforms also support integration with genetic and omics data, enhancing personalization and relevance [13,14]. Omics data integration allows for the incorporation of genomic, proteomic, and metabolomic variations into simulations, thereby facilitating the exploration of interindividual variability in drug responses. This capability is essential for advancing precision medicine, as it enables the identification of patient subgroups most likely to benefit from, or be harmed by, specific therapeutic interventions.

Advanced computational techniques, including machine learning (ML) and artificial intelligence (AI), are increasingly employed to refine model parameters, forecast outcomes, and automate the development of predictive models. Machine learning algorithms, particularly those based on supervised and unsupervised learning techniques, can analyze vast datasets to identify patterns, optimize simulation parameters, and predict pharmacokinetic and pharmacodynamic outcomes with greater accuracy. Similarly, AI approaches enable automated hypothesis generation, model validation, and adaptive learning, enhancing the robustness and predictive power of in-silico pharmacology platforms.

For instance, ML algorithms can optimize PBPK parameters based on large-scale clinical and experimental data, while AI-driven natural language processing (NLP) tools extract critical information from scientific literature and clinical records. Machine learning-driven parameter optimization reduces human bias and improves model calibration by systematically analyzing complex datasets, while NLP applications allow researchers to rapidly mine vast volumes of textual data to retrieve relevant biological insights, drug-related findings, and clinical trial results. Collectively, these technological advancements significantly enhance the scalability, speed, and precision of virtual human model development, accelerating the transition from traditional experimental approaches to data-driven, computationally enabled drug discovery [9,18,24,29,32,33,36,40].

Figure 3: Model generated by AI for Pharmacokinetic and Pharmacodynamic studies

COMPUTATIONAL FINDINGS

The application of virtual human models in drug development has yielded promising results across several domains, demonstrating their potential to revolutionize traditional research and clinical paradigms.

Target Identification and Validation

In-silico approaches enable high-throughput analysis of biological pathways to identify molecular targets implicated in disease mechanisms. These computational methods allow researchers to systematically explore complex biological networks and discover key molecules that play central roles in pathological processes. Systems biology techniques and network pharmacology enhanced by AI tools help researchers visualize complex interactions between genes, proteins, and metabolites.

This integrated visualization provides a systems-level understanding of disease mechanisms and facilitates the identification of critical nodes or hubs within biological networks. This allows for the identification of highly connected nodes or hubs, often representing potential drug targets. Highly interconnected molecules are usually pivotal in maintaining network stability and, thus, represent attractive targets for therapeutic intervention.

Genetic variability, post-translational modifications, and feedback loops can also be incorporated to assess the functional viability of proposed targets [3,14,17,28]. These enhancements improve the accuracy of target validation, ensuring that selected molecules are biologically relevant and clinically actionable.[39,42]



Figure 4: Molecular target identification and validation

Dose Optimization

Virtual human avatars offer a controlled platform to test and refine drug dosing strategies. By simulating virtual patients with varying physiological and pathological conditions, researchers can fine-tune dosing regimens before clinical trials. PBPK simulations are particularly useful for evaluating how inter-individual differences such as age, weight, gender, organ function, and genetic makeup which influence drug pharmacokinetics and pharmacodynamics.

This leads to tailored dosing regimens that minimize adverse effects and optimize therapeutic outcomes. The ability to simulate vulnerable populations such as children, elderly individuals, pregnant women, and patients with organ dysfunction enhances the precision of dosing recommendations. For instance, dose adjustments for renal or hepatic impairment can be modeled without exposing patients to risk [13,15], significantly improving safety profiles and therapeutic efficacy even before entering human studies.

Figure 5: Virtual human avatars

Toxicity Prediction

One of the most significant advantages of in-silico pharmacology is its capability to predict toxicity and adverse drug reactions before clinical exposure. Early toxicity prediction can greatly reduce the likelihood of late-stage drug failures, which are costly and time-consuming. Platforms like DILIsym® are engineered to model drug-induced liver injury

(DILI) by simulating molecular and cellular responses in hepatic tissue.

These specialized models integrate biochemical pathways involved in liver metabolism and immune responses to forecast potential hepatotoxic effects. These tools use compound-specific input data to predict hepatotoxicity, enabling researchers to either refine the drug structure or modify dosing strategies early in development.

Early identification of hepatotoxic compounds can prevent costly withdrawals and adverse outcomes. Moreover, simulations of cardiotoxicity, nephrotoxicity, and neurotoxicity are being developed to broaden the safety assessment scope [14,20,38,43], offering comprehensive preclinical safety profiling across multiple organ systems.



Figure 6: Hepatotoxic study model

Figure 7: Virtual reality based animal model for toxicity studies

Virtual Clinical Trials

The concept of virtual clinical trials represents a disruptive innovation in clinical research. Traditional trials are expensive, time-consuming, and often limited by recruitment challenges and population heterogeneity. In contrast, virtual clinical trials simulate heterogeneous virtual populations that account for demographic, genetic, and disease-specific variability. Trial scenarios ranging from placebo-controlled to crossover designs can be tested rapidly and cost-effectively. These simulations can predict trial outcomes, identify confounding variables, and optimize trial protocols before real-world implementation.

The results offer preliminary efficacy and safety profiles, which guide subsequent real-world trial design. Digital twins, i.e., virtual replicas of individual patients, enhance this approach by providing real-time feedback and predictive outcomes for therapeutic interventions, marking a paradigm shift toward more personalized and efficient clinical research [21,22,23,28,35,41,44].

Figure 8: Virtual Human models used for Clinical Studies

Figure 9: Virtual Reality developed Clinical trials

AI and ML Applications

AI and ML are integral to improving the predictive power of in-silico models. Their ability to handle large, complex datasets transforms model accuracy and utility. These technologies assist in data integration, pattern recognition, and hypothesis generation, accelerating drug discovery and development processes. Deep learning algorithms have shown effectiveness in analyzing high-dimensional datasets such as medical imaging, omics data, and real-world evidence. They uncover hidden patterns and relationships that might be missed by traditional statistical methods. They are used in virtual screening of compounds, de-novo drug design, and adverse effect prediction, leading to faster identification of promising drug candidates. NLP algorithms extract meaningful insights from unstructured data sources, such as biomedical publications, clinical notes, and regulatory documents, enhancing the knowledge base used in simulations. These advances make virtual human models more robust, comprehensive, and capable of supporting data-driven decision-making in healthcare and pharmacology [9,18,24,29,45].

Figure 10: Machine learning in Clinical Studies

DISCUSSION

Digital Twins in Precision Medicine

Digital twins are at the frontier of personalized medicine. Unlike static models, digital twins evolve continuously, offering dynamic, individualized simulations. Constructed from real-time patient data encompassing electronic health records, genomics, proteomics, metabolomics, and data from wearable devices these models provide a continuously evolving representation of the patient's health status. This continuous update enables clinicians to adapt treatment plans promptly as patient conditions change. Clinicians can simulate various treatment scenarios, evaluate potential risks, and select optimal therapeutic strategies for chronic and complex conditions such as diabetes, cardiovascular diseases, and cancers. This predictive capability empowers proactive, rather than reactive, medical interventions. These platforms are now being integrated into hospital systems, enabling proactive and preventive healthcare delivery [16,27,30], promising a significant leap toward truly individualized medicine.



Figure 11: AI Developed Digital Human Twins

Regulatory Acceptance and Frameworks

Regulatory bodies have begun to formally recognize the value of in-silico methods. This acknowledgment has catalyzed greater investment and integration of computational models in pharmaceutical research. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guidelines on the use of PBPK modeling in regulatory submissions. These guidelines validate the scientific rigor of computational methods and encourage their adoption for critical regulatory decisions. In many cases, PBPK data has been used to justify first-in-human dosing, predict drug-drug interactions (DDIs), and support extrapolation to special populations. This helps in making early and safer clinical trial decisions. Regulatory pilot programs now include AI and digital health tools, setting the stage for broader acceptance of virtual clinical trials. As a result, the drug development process becomes more streamlined and predictive. This shift not only shortens the time to market but also improves transparency, reproducibility, and patient safety, heralding a new era in regulatory science. [5,13,22,23,27,34]

Limitations and Ethical Concerns

Despite their promise, virtual human models face limitations that must be addressed to maximize their utility and trustworthiness.

Data Limitations: Many physiological and pathological processes remain incompletely characterized. Even sophisticated models are only as good as the data they are built upon. Lack of high-quality data can compromise model fidelity and predictive accuracy, leading to erroneous conclusions or missed therapeutic opportunities.

Model Validation: Validation against real-world clinical outcomes is essential to ensure reliability. Without rigorous validation, there is a risk of over fitting or inaccurate simulations. Ongoing efforts focus on improving standardization and reproducibility, including collaborative validation frameworks among academia, industry, and regulatory agencies.

Computational Demands: High-resolution models require significant computational resources, which can limit access for smaller institutions. The need for high-performance computing infrastructure can create disparities in research capabilities, potentially slowing innovation in less-resourced environments.

Interoperability: Lack of standard data formats and integration capabilities poses challenges for clinical adoption. Seamless integration of diverse data types from imaging and omics to clinical records is critical but remains technically and administratively difficult.

Ethical Concerns: Digital twins involve sensitive personal data, raising issues related to privacy, consent, data ownership, and algorithmic bias. The potential misuse or mishandling of sensitive health data is a serious concern. Ethical frameworks and compliance with regulations such as GDPR are crucial to ensure patient trust and protect individual rights. Additionally, efforts must be made to eliminate biases that could disproportionately harm certain population groups through unfair or inaccurate model predictions [5,11,12,24,30].

CONCLUSION

In-silico pharmacology, particularly through the use of virtual human models, is revolutionizing drug discovery, development, and delivery. These computational models provide numerous benefits, such as cost efficiency, ethical transparency, accelerated timelines, and the ability to personalize treatments. By simulating human biological processes, these models allow researchers to predict drug behavior, optimize dosing, and assess potential side effects long before clinical trials.The integration of Physiologically-Based Pharmacokinetic (PBPK) modeling, Artificial Intelligence (AI), Machine Learning (ML), and digital twin technology enhances the precision and scalability of these

tools. These technologies enable the creation of patient-specific simulations that account for genetic diversity, disease conditions, and environmental factors, leading to improved drug efficacy and safety profiles. The future of virtual humans in drug development is closely tied to advancements in data science, computational power, and regulatory evolution. As computational techniques, such as quantum and edge computing, evolve, the accuracy of simulations will improve, allowing real-time predictions. Additionally, regulatory frameworks that embrace model-informed drug development will facilitate the adoption of these technologies in clinical trials. Moreover, real-time physiological monitoring through wearables and blockchain for secure data sharing will further enhance the accuracy and security of virtual human models. Interdisciplinary education programs will also play a critical role in advancing this field. In the coming years, virtual humans will become integral to creating a more efficient, ethical, and patient-centered drug development process, leading to safer and more personalized treatments.

REFERENCES

1. Badhe Y, Gupta R, Rai B. Virtual screening of natural compounds as potential inhibitors of SARS-CoV-2 main protease. *Bioinformation*. 2020;16(5):385–90.
2. Raj U, Varadwaj PK. Flavonoids as potential inhibitors against SARS-CoV-2 main protease. *Bioinformation*. 2020;16(3):236–42.
3. Anwar S, Wahid B. In silico analysis of pharmacokinetic properties of repurposed drugs against SARS-CoV-2. *Bioinformation*. 2020;16(6):426–31.
4. Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the "bottom up" and "top down" approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. *Br J Clin Pharmacol*. 2015;79(1):48–55.
5. Musuamba FT, Skottheim Rusten I, Lesage R, de Béthune MP. Model-informed drug development in the era of precision medicine: state of the art and future trends. *CPT Pharmacometrics Syst Pharmacol*. 2021;10(2):120–4.
6. Viceconti M, Hunter P, Hose R. Big data, big knowledge: big data for personalized healthcare. *IEEE J Biomed Health Inform*. 2015;19(4):1209–15.
7. Hunter P, Viceconti M. The VPH-Physiome Project: standards and tools. *Interface Focus*. 2013;3(2):20120081.
8. Ghosh S, Maiti S. Virtual screening and drug design: computational chemistry approaches for lead discovery. *Bioinformation*. 2022;18(7):584–90.
9. Zhang Q, Liu T, Ng DW, Xu L. A machine learning-based drug repositioning framework for combating COVID-19. *Bioinformation*. 2020;16(6):470–8.
10. Guo Y, et al. Integration of systems biology and virtual human modeling to assess cancer therapies. *Curr Pharm Des*. 2014;20(30):4956–65.
11. Crampin EJ, Smith NP, Hunter PJ. Multi-scale modelling and the IUPS Physiome Project. *J Mol Histol*. 2004;35(7):707–14.
12. Musuamba FT, et al. Challenges in using modeling approaches in pediatric drug development. *Front Pediatr*. 2021;9:642447.
13. Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. *Clin Pharmacol Ther*. 2017;101(5):646–56.
14. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. *Annu Rev Pharmacol Toxicol*. 2011;51:45–73.
15. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. *Clin Pharmacol Ther*. 2011;89(2):259–67.
16. Corral-Acero J, et al. The 'digital twin' to enable the vision of precision cardiology. *Eur Heart J*. 2020;41(48):4556–64.
17. Hege HC, et al. Modeling blood flow and oxygen transport in virtual human organs. *Acta Numer*. 2018;27:103–90.
18. Sakharkar MK, Sakharkar KR. Predicting therapeutic targets by computational gene network analysis. *Bioinformation*. 2013;9(8):396–402.
19. Sathe A, et al. Identification of potential novel targets for colorectal cancer using network pharmacology and molecular docking. *Bioinformation*. 2021;17(3):327–36.
20. Woodhead JL, et al. Analyzing the mechanism of drug-induced liver injury with DILIsym®. *Clin Pharmacol Ther*. 2017;101(4):490–8.
21. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. *CPT Pharmacometrics Syst Pharmacol*. 2012;1(9):e6.
22. European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf
23. US FDA. Physiologically Based Pharmacokinetic Analyses – Format and Content Guidance for Industry. 2018. Available from: https://www.fda.gov/media/101469/download
24. Sakharkar KR, Sakharkar MK. Artificial intelligence in drug development. *Bioinformation*. 2020;16(4):301–4.
25. Liu X, et al. Applications of PBPK modeling and simulation in regulatory decision making and its influence on drug development. *J Clin Pharmacol*. 2020;60(S1):S3–17.
26. Agrawal R, et al. A review on predictive modeling of COVID-19 using AI. *Bioinformation*. 2020;16(3):288–94.
27. Polasek TM, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualised dosing at scale. *Clin Pharmacokinet*. 2018;57(5):665–76.
28. Jain S, Patel A, Chauhan N. Computational modeling in cardiovascular medicine. *Bioinformation*. 2021;17(8):697–702.
29. Mukherjee R, Satyanarayana U, Neogi S. Systems biology approach in metabolic disease modeling. *Bioinformation*. 2015;11(7):342–6.
30. Pant K, Yadav AK. Digital twin in healthcare: concept, architecture, and challenges. *Bioinformation*. 2021;17(9):810–6.
31. Viceconti M, Hunter P. The Virtual Physiological Human: ten years after. *Annu Rev Biomed Eng*. 2016;18:103–23.
32. Eissing T, Kuepfer L, Becker C, et al. A model-based approach to dose selection and efficacy prediction in early clinical drug development. *CPT Pharmacometrics Syst Pharmacol*. 2011;1(1):e13.
33. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. *Clin Pharmacokinet*. 2006;45(10):1013–34.
34. Pappalardo F, Russo G, Tshinanu FM, Viceconti M. In silico clinical trials: concepts and early adoptions. *Brief Bioinform*. 2019;20(5):1699–708.
35. Kovatchev B, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. *J Diabetes Sci Technol*. 2009;3(1):44–55.
36. Allen RJ, Eissing T, Lippert J. Modeling and simulation for pediatric drug development. *Clin Pharmacol Ther*. 2016;100(4):362–75.
37. Henney AM, Coaker SJ, Gavaghan DJ. The Virtual Physiological Human: exploring the role of informatics in integrative bioscience. *J R Soc Interface*. 2008;5(Suppl 3):S131–8.

38. Musuamba FT, Manolis E, Holford N, et al. Advanced methods for dose exposure–response modeling in drug development: recent trends and perspectives. *Br J Clin Pharmacol*. 2021;87(6):2197–212.

39. Vass A, Podhajska A, Kis A, Papp R, Cserey G. Predicting pharmacokinetic parameters from chemical structure using deep learning. *J Cheminform*. 2021;13(1):1–14.

40. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug research and development. *CPT Pharmacometrics Syst Pharmacol*. 2015;4(2):69–76.

41. Pappalardo F, Pennisi M, Ricupito A, Viceconti M. Agent-based modeling and simulation in computational immunology. *Immunol Rev*. 2014;261(1):134–47.

42. Chary KVK, Ramanathan M, Rajkumar J. Application of artificial intelligence in drug discovery and development. *Biomed Pharmacother*. 2022;153:113325.

43. Jeliazkova N, Jeliazkov V, Georgiev I. Tools for read-across and in silico modeling in toxicology. *Comput Toxicol*. 2021;18:100163.

44. Lal MA, La Colla L, Bonazzi D, Shorten G, Razi M. Digital health and AI in drug development and personalized care. *Nat Rev Drug Discov*. 2022;21(11):797–8.

45. Kotecha K, Garg N. Applications of ML in the pharma industry: a case-based perspective. *Expert Opin Drug Discov*. 2021;16(10):1115–25.